Baxter International (BAX) to Release Earnings on Thursday

Baxter International (NYSE:BAX) is expected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Baxter International to post earnings of $0.53 per share and revenue of $2.8248 billion for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Baxter International Stock Up 5.8%

BAX stock opened at $21.06 on Thursday. Baxter International has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.84 and a quick ratio of 1.18. The stock has a market capitalization of $10.83 billion, a price-to-earnings ratio of -31.91, a PEG ratio of 1.16 and a beta of 0.59. The business’s fifty day moving average price is $19.46 and its two-hundred day moving average price is $21.56.

Baxter International Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Friday, November 28th were given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend was Friday, November 28th. Baxter International’s dividend payout ratio (DPR) is currently -6.06%.

Institutional Trading of Baxter International

A number of hedge funds have recently added to or reduced their stakes in BAX. Imprint Wealth LLC acquired a new position in shares of Baxter International during the third quarter worth $27,000. MUFG Securities EMEA plc acquired a new stake in shares of Baxter International during the 2nd quarter valued at $46,000. Parallel Advisors LLC grew its position in Baxter International by 113.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,971 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 2,109 shares during the last quarter. United Capital Financial Advisors LLC increased its holdings in Baxter International by 19.2% in the 3rd quarter. United Capital Financial Advisors LLC now owns 10,539 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 1,694 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S increased its holdings in Baxter International by 21.4% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after purchasing an additional 4,293 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BAX. The Goldman Sachs Group increased their target price on shares of Baxter International from $22.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, January 9th. Barclays cut their price target on Baxter International from $36.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a report on Wednesday, January 21st. Finally, Zacks Research downgraded Baxter International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Baxter International has a consensus rating of “Reduce” and a consensus price target of $21.40.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.